X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ALEMBIC LTD - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ALEMBIC LTD WYETH LTD/
ALEMBIC LTD
 
P/E (TTM) x 27.7 51.4 53.9% View Chart
P/BV x 5.3 2.2 243.1% View Chart
Dividend Yield % 1.3 0.5 274.8%  

Financials

 WYETH LTD   ALEMBIC LTD
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ALEMBIC LTD
Mar-18
WYETH LTD/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,04472 1,450.6%   
Low Rs81834 2,413.0%   
Sales per share (Unadj.) Rs298.64.7 6,351.6%  
Earnings per share (Unadj.) Rs57.26.1 937.8%  
Cash flow per share (Unadj.) Rs58.46.2 935.3%  
Dividends per share (Unadj.) Rs17.000.20 8,500.0%  
Dividend yield (eoy) %1.80.4 483.3%  
Book value per share (Unadj.) Rs249.540.7 613.5%  
Shares outstanding (eoy) m22.72267.03 8.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.111.3 27.7%   
Avg P/E ratio x16.38.7 187.5%  
P/CF ratio (eoy) x15.98.5 188.0%  
Price / Book Value ratio x3.71.3 286.6%  
Dividend payout %29.73.3 906.4%   
Avg Mkt Cap Rs m21,15714,139 149.6%   
No. of employees `0000.5NA-   
Total wages/salary Rs m400207 192.9%   
Avg. sales/employee Rs Th13,787.4NM-  
Avg. wages/employee Rs Th813.0NM-  
Avg. net profit/employee Rs Th2,643.3NM-  
INCOME DATA
Net Sales Rs m6,7831,255 540.4%  
Other income Rs m353370 95.2%   
Total revenues Rs m7,1361,625 439.0%   
Gross profit Rs m1,617111 1,455.7%  
Depreciation Rs m2738 70.4%   
Interest Rs m62 323.5%   
Profit before tax Rs m1,938442 438.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m63224 2,639.7%   
Profit after tax Rs m1,3011,630 79.8%  
Gross profit margin %23.88.9 269.4%  
Effective tax rate %32.65.4 601.8%   
Net profit margin %19.2129.8 14.8%  
BALANCE SHEET DATA
Current assets Rs m6,9841,867 374.1%   
Current liabilities Rs m2,056591 347.8%   
Net working cap to sales %72.6101.6 71.5%  
Current ratio x3.43.2 107.6%  
Inventory Days Days9994 105.3%  
Debtors Days Days2474 32.6%  
Net fixed assets Rs m2441,791 13.6%   
Share capital Rs m227534 42.5%   
"Free" reserves Rs m5,44110,324 52.7%   
Net worth Rs m5,66810,858 52.2%   
Long term debt Rs m2541 60.7%   
Total assets Rs m7,90111,591 68.2%  
Interest coverage x353.3260.9 135.4%   
Debt to equity ratio x00 116.2%  
Sales to assets ratio x0.90.1 792.8%   
Return on assets %16.514.1 117.4%  
Return on equity %22.915.0 152.9%  
Return on capital %34.015.2 224.1%  
Exports to sales %0.21.5 14.1%   
Imports to sales %36.321.0 173.2%   
Exports (fob) Rs m1519 76.3%   
Imports (cif) Rs m2,465263 936.2%   
Fx inflow Rs m1519 78.4%   
Fx outflow Rs m2,677264 1,014.8%   
Net fx Rs m-2,662-244 1,089.1%   
CASH FLOW
From Operations Rs m923236 391.5%  
From Investments Rs m317-224 -141.5%  
From Financial Activity Rs m-481-27 1,808.3%  
Net Cashflow Rs m759-15 -5,129.1%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.2 5,650.0%  
FIIs % 7.2 9.7 74.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 26.1 116.5%  
Shareholders   21,978 54,701 40.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  SHASUN PHARMA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - AJANTA PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS